Trial · NCT06705062
Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation
NCT06705062, Phase 3, Recruiting, Shanghai Jiao Tong University School of Medicine
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation. Trials, record NCT06705062. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06705062
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation
- NCT number
- NCT06705062
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 316 participants, estimated
- Lead sponsor
- Shanghai Jiao Tong University School of Medicine
- Conditions
- Allogeneic Hematopoietic Cell Transplant, Graft Versus Host Disease
- Interventions
- reduced-dose PTCy, Standard dose PTCY
- First posted
- 2024-11-26
- Last updated
- 2026-03-17
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 100-day II-IV acute GVHD | 100 day | Patients diagnosed with grade II-IV acute GVHD within 100 day after allo-HSCT |
| Secondary | 100-day acute GVHD | 100 day | Patients diagnosed with aGVHD of all grades within 100 days after allo-HSCT |
| Secondary | 100-day non-relapse mortality | 100 day | Patients died of any causes without documentation of disease relapse or progression at day 100 after allo-HSCT |
| Secondary | 1-year chronic GVHD | 1 year | Patients diagnosed with chronic GVHD of all grades at 1 year after allo-HSCT |
| Secondary | 1-year moderate to severe chronic GVHD | 1 year | Patients diagnosed with moderate to severe chronic GVHD at 1 year after allo-HSCT |
| Secondary | 1-year NRM | 1 year | Patients died of any causes without documentation of relapse or disease progression 1 year after allo-HSCT |
| Secondary | 1-year cumulated incidence of relapse | 1 year | Patients died of relapse or disease progression 1 year after allo-HSCT |
| Secondary | 1-year overall survival | 1 year | Patients remained alive at 1 year after allo-HSCT |
| Secondary | 1-year graft host disease free and relapse free survival | 1 year | Patients remained alive without relapse, grade III-IV aGVHD or moderate to severe chronic GVHD |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06705062
GET https://conductscience.org/api/trials/v1/NCT06705062/registered